Improved therapy for neuroblastoma using a combination approach: Superior efficacy with vismodegib and topotecan

Nagendra K. Chaturvedi, Timothy R McGuire, Donald W Coulter, Ashima Shukla, Erin M. McIntyre, John G Sharp, Shantaram S Joshi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aberrant activation/expression of pathways/molecules including NF-kB, mTOR, hedgehog and polo-like-kinase-1 (PLK1) are correlated with poor-prognosis neuroblastoma. Therefore, to identify a most efficacious treatment for neuroblastoma, we investigated the efficacy of NF-kB/mTOR dual-inhibitor 13-197, hedgehog inhibitor vismodegib and PLK1 inhibitor BI2536 alone or combined with topotecan against high-risk neuroblastoma. The in vitro efficacy of the inhibitors alone or combined with topotecan on cell growth/apoptosis and molecular mechanism(s) were investigated. Results showed that as single agents 13-197, BI2536 and vismodegib significantly decreased neuroblastoma cell growth and induced apoptosis by targeting associated pathways/molecules. In combination with topotecan, 13-197 did not show significant additive/synergistic effects against neuroblastoma. However, BI2536 or vismodegib further significantly decreased neuroblastoma cell growth/survival. These results clearly showed that vismodegib combination with topotecan was synergistic and more efficacious compared with BI2536 in combination. Together, in vitro data demonstrated that vismodegib was most efficacious in potentiating topotecan-induced antineuroblastoma effects. Therefore, we tested the combined efficacy of vismodegib and topotecan against neuroblastoma in vivo using NSG mice. This resulted in significantly (p<0.001) reduced tumor growth and increased survival of mice. Together, the combination of vismodegib and topotecan showed a significant enhanced antineuroblastoma efficacy by targeting associated pathways/molecules which warrants further preclinical evaluation for translation to the clinic.

Original languageEnglish (US)
Pages (from-to)15215-15229
Number of pages15
JournalOncotarget
Volume7
Issue number12
DOIs
StatePublished - Mar 22 2016

Fingerprint

HhAntag691
Topotecan
Neuroblastoma
Hedgehogs
NF-kappa B
Growth
Therapeutics
Apoptosis
Cell Survival

Keywords

  • Chemotherapy
  • Hedgehog inhibitor
  • MYCN
  • Neuroblastoma
  • Small molecule inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Improved therapy for neuroblastoma using a combination approach : Superior efficacy with vismodegib and topotecan. / Chaturvedi, Nagendra K.; McGuire, Timothy R; Coulter, Donald W; Shukla, Ashima; McIntyre, Erin M.; Sharp, John G; Joshi, Shantaram S.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 15215-15229.

Research output: Contribution to journalArticle

@article{1d8cc7a9b5ad429fa380d3fc855224a5,
title = "Improved therapy for neuroblastoma using a combination approach: Superior efficacy with vismodegib and topotecan",
abstract = "Aberrant activation/expression of pathways/molecules including NF-kB, mTOR, hedgehog and polo-like-kinase-1 (PLK1) are correlated with poor-prognosis neuroblastoma. Therefore, to identify a most efficacious treatment for neuroblastoma, we investigated the efficacy of NF-kB/mTOR dual-inhibitor 13-197, hedgehog inhibitor vismodegib and PLK1 inhibitor BI2536 alone or combined with topotecan against high-risk neuroblastoma. The in vitro efficacy of the inhibitors alone or combined with topotecan on cell growth/apoptosis and molecular mechanism(s) were investigated. Results showed that as single agents 13-197, BI2536 and vismodegib significantly decreased neuroblastoma cell growth and induced apoptosis by targeting associated pathways/molecules. In combination with topotecan, 13-197 did not show significant additive/synergistic effects against neuroblastoma. However, BI2536 or vismodegib further significantly decreased neuroblastoma cell growth/survival. These results clearly showed that vismodegib combination with topotecan was synergistic and more efficacious compared with BI2536 in combination. Together, in vitro data demonstrated that vismodegib was most efficacious in potentiating topotecan-induced antineuroblastoma effects. Therefore, we tested the combined efficacy of vismodegib and topotecan against neuroblastoma in vivo using NSG mice. This resulted in significantly (p<0.001) reduced tumor growth and increased survival of mice. Together, the combination of vismodegib and topotecan showed a significant enhanced antineuroblastoma efficacy by targeting associated pathways/molecules which warrants further preclinical evaluation for translation to the clinic.",
keywords = "Chemotherapy, Hedgehog inhibitor, MYCN, Neuroblastoma, Small molecule inhibitors",
author = "Chaturvedi, {Nagendra K.} and McGuire, {Timothy R} and Coulter, {Donald W} and Ashima Shukla and McIntyre, {Erin M.} and Sharp, {John G} and Joshi, {Shantaram S}",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7714",
language = "English (US)",
volume = "7",
pages = "15215--15229",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - Improved therapy for neuroblastoma using a combination approach

T2 - Superior efficacy with vismodegib and topotecan

AU - Chaturvedi, Nagendra K.

AU - McGuire, Timothy R

AU - Coulter, Donald W

AU - Shukla, Ashima

AU - McIntyre, Erin M.

AU - Sharp, John G

AU - Joshi, Shantaram S

PY - 2016/3/22

Y1 - 2016/3/22

N2 - Aberrant activation/expression of pathways/molecules including NF-kB, mTOR, hedgehog and polo-like-kinase-1 (PLK1) are correlated with poor-prognosis neuroblastoma. Therefore, to identify a most efficacious treatment for neuroblastoma, we investigated the efficacy of NF-kB/mTOR dual-inhibitor 13-197, hedgehog inhibitor vismodegib and PLK1 inhibitor BI2536 alone or combined with topotecan against high-risk neuroblastoma. The in vitro efficacy of the inhibitors alone or combined with topotecan on cell growth/apoptosis and molecular mechanism(s) were investigated. Results showed that as single agents 13-197, BI2536 and vismodegib significantly decreased neuroblastoma cell growth and induced apoptosis by targeting associated pathways/molecules. In combination with topotecan, 13-197 did not show significant additive/synergistic effects against neuroblastoma. However, BI2536 or vismodegib further significantly decreased neuroblastoma cell growth/survival. These results clearly showed that vismodegib combination with topotecan was synergistic and more efficacious compared with BI2536 in combination. Together, in vitro data demonstrated that vismodegib was most efficacious in potentiating topotecan-induced antineuroblastoma effects. Therefore, we tested the combined efficacy of vismodegib and topotecan against neuroblastoma in vivo using NSG mice. This resulted in significantly (p<0.001) reduced tumor growth and increased survival of mice. Together, the combination of vismodegib and topotecan showed a significant enhanced antineuroblastoma efficacy by targeting associated pathways/molecules which warrants further preclinical evaluation for translation to the clinic.

AB - Aberrant activation/expression of pathways/molecules including NF-kB, mTOR, hedgehog and polo-like-kinase-1 (PLK1) are correlated with poor-prognosis neuroblastoma. Therefore, to identify a most efficacious treatment for neuroblastoma, we investigated the efficacy of NF-kB/mTOR dual-inhibitor 13-197, hedgehog inhibitor vismodegib and PLK1 inhibitor BI2536 alone or combined with topotecan against high-risk neuroblastoma. The in vitro efficacy of the inhibitors alone or combined with topotecan on cell growth/apoptosis and molecular mechanism(s) were investigated. Results showed that as single agents 13-197, BI2536 and vismodegib significantly decreased neuroblastoma cell growth and induced apoptosis by targeting associated pathways/molecules. In combination with topotecan, 13-197 did not show significant additive/synergistic effects against neuroblastoma. However, BI2536 or vismodegib further significantly decreased neuroblastoma cell growth/survival. These results clearly showed that vismodegib combination with topotecan was synergistic and more efficacious compared with BI2536 in combination. Together, in vitro data demonstrated that vismodegib was most efficacious in potentiating topotecan-induced antineuroblastoma effects. Therefore, we tested the combined efficacy of vismodegib and topotecan against neuroblastoma in vivo using NSG mice. This resulted in significantly (p<0.001) reduced tumor growth and increased survival of mice. Together, the combination of vismodegib and topotecan showed a significant enhanced antineuroblastoma efficacy by targeting associated pathways/molecules which warrants further preclinical evaluation for translation to the clinic.

KW - Chemotherapy

KW - Hedgehog inhibitor

KW - MYCN

KW - Neuroblastoma

KW - Small molecule inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84962859890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962859890&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7714

DO - 10.18632/oncotarget.7714

M3 - Article

C2 - 26934655

AN - SCOPUS:84962859890

VL - 7

SP - 15215

EP - 15229

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -